User:Jorgeq13/DAPIVIRINE

Dapivirine (TMC 120) is a potent non-nucleoside reverse transcriptase inhibitor (NNRTI) that is presently in development as a vaginal HIV microbicide. Dapivirine, a substituted diarylpyrimidine analogue, is one of a new generation of NNRTIs that can accommodate some mutations within the NNRTI binding site without significant loss of activity. Dapivirine displays improved activity against both wild-type strains of HIV-1 and strains harboring different mutations inducing resistance to other NNRTIs, and data show that dapivirine has a resistance profile superior to those of existing NNRTIs such as nevirapine, delavirdine and efavirenz

Pre-clinical and clinical testing has shown Dapivirine to have a favorable safety profile when administered orally as a therapeutic drug for HIV/AIDS or intravaginally as a microbicide for the prevention of HIV infection.

A strategy to prevent sexual transmission of HIV is the use of topical microbicides that could be controlled by women. To date, most vaginal microbicides under clinical investigation have been formulated as single-dose semi-solid gels, designed for application to the vagina before each act of intercourse. Recently, polyether urethanes intravaginal rings have been developed for sustained delivery of microbicidal agents. Silicone intravaginal rings allow sustained release for as long as 70 days.